Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

FDA Approves Latisse Eyelash Drug

Posted by Chrissie Cole
Sunday, December 28, 2008 11:10 PM EST
Category: Miscellaneous
Tags: FDA and Prescription Drugs, Allegran, Latisse, Lumigan, Cosmetics


IMAGE SOURCE: Wikimedia Commons/ thick eyelashes/ author: Chameleon

The first drug to promote eyelash growth has been approved by the U.S. Food and Drug Administration (FDA) and will be available for prescription the first half of 2009.

Latisse (bimatoprost ophthalmic solution), approved for hypotrichosis, contains the active ingredient of the glaucoma drug Lumigan – both of which are made by Allergan.

Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.

A known side effect of the drug Lumigan is eyelash growth. But Latisse and Lumigan are applied differently. While Latisse gets applied along the lash line on the upper eyelid, Lumigan is an eyedrop.

“Latisse users can expect longer, thicker and darker lashes in as little as eight weeks, will full results in 16 weeks,” Allergan states. If Latisse is stopped, eyelashes will slowly return to their previous appearance.

Latisse may cause some darkening of the eyelid skin which may be reversible. Although not reported in clinical trials, Latisse “may cause increased brown pigmentation of the colored part of the eye, which is most likely permanent,” reports the company.

It is possible for hair growth to occur in other areas of your skin that Latisse frequently touches. Any excess solution should be blotted with a tissue to prevent this from happening.

Well-tolerated in its clinical trials, the most common side effects of Latisse are itchy eyes and/or eye redness. Less common side effects include dryness of the eyes, redness of the eyelids and skin hyperpigmentation (darkening of an area of skin), according to Allergan.

An FDA advisory panel, earlier this month, recommended that the FDA approve Latisse and also suggested post-approval studies on certain patient populations, including patients of younger age and post-chemotherapy patients with loss of eyelashes. #

No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes